<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03012867</url>
  </required_header>
  <id_info>
    <org_study_id>NUTR1</org_study_id>
    <nct_id>NCT03012867</nct_id>
  </id_info>
  <brief_title>Enteral Nutrition and Glucose Homeostasis</brief_title>
  <official_title>Effect of Different Enteral Nutrition Formulas on Glucose Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Different enteral nutrition formulas are tested on their effect on glucose homeostasis in&#xD;
      critically ill medical patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess whether enteral nutrition fomulas based either on fat or glucose influence glucose&#xD;
      homeostasis differently in critically ill medical patients. All patients are admitted to a&#xD;
      tertiary ICU and require mechanical ventilation.&#xD;
&#xD;
      Resting energy expenditure is assessed at baseline in the fasting state by indirect&#xD;
      calorimetry. Total energy demand is calculated and patients are randomized to receive&#xD;
      fat-based or glucose-based nutrition which is administered continously for 7 days. Indirect&#xD;
      calorimetry is repeated on days 3 and 7 under continous nutrition. During the study period,&#xD;
      various parameters of glucose homeostasis are assessed. Daily, there will be at least 3&#xD;
      measurements of blood glucose, more if the treating physician deems it necessary. Daily&#xD;
      average glucose, daily glucose variability, overall area under the curve for glucose are&#xD;
      calculated. Furthermore, energy intake by nutrition, medications (i.e. propofol), and glucose&#xD;
      infusion, as well as substrate intake, and insulin demand per 24hrs are determined daily.&#xD;
      Adverse effects such as episodes of hyper- or hypoglycemia, cholestasis,&#xD;
      hypertriglyceridemia, diarrhea, vomiting, and the amount of gastric residual volume are&#xD;
      noted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>average daily glucose</measure>
    <time_frame>up to 7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin demand per 24 hrs</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose variability</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nutrition-related side effects</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hyperglycemia Stress</condition>
  <arm_group>
    <arm_group_label>fat-based</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>glucose-based</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diben, Fresenius Kabi</intervention_name>
    <description>Patients receive Diben continously for 7 days</description>
    <arm_group_label>fat-based</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fresubin original fibre, Fresenius Kabi</intervention_name>
    <description>Patients receive Fresubin original fibre continously for 7 days</description>
    <arm_group_label>glucose-based</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  medical patient with need for mechanical ventilation&#xD;
&#xD;
          -  FiO2 requirement &lt; 60%&#xD;
&#xD;
          -  need for nutritional support&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindications against nutritional therapy&#xD;
&#xD;
          -  hemodynamic shock (lactate of ≥ 4 mmol/l)&#xD;
&#xD;
          -  severe hypertriglyceridemia (≥ 450 mg/dl)&#xD;
&#xD;
          -  contraindications against enteral nutrion (intestinal obstruction, disruption or&#xD;
             severe bleeding of upper gastrointestinal tract)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Zauner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>January 5, 2017</last_update_submitted>
  <last_update_submitted_qc>January 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Marlene Wewalka</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>criticall illness</keyword>
  <keyword>enteral nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

